Grant

In Vivo Anti-Cancer Activity of CB-5339 In Combination with PARP Inhibitor Olaparib in the MX-1 Breast Cancer Model

$38.6K Funding

2 People

External

Related Topics

cancer, parp inhibitor, breast cancer, in vivo, combination therapy

People

Jennifer Carew
Principal Investigator (PI)
Medicine﹒Professor
Steffan Nawrocki
Co-Investigator (COI)
Medicine﹒Professor